PL-8177: the oral melanocortin trying to calm inflammation from inside the gut

The system's calming arm, held to one place — a melanocortin told to settle the gut and go no further.

PL-8177 is a good reminder that the melanocortin system does more than pigment and appetite. Its third great role is calming inflammation — the natural signal α-MSH is a potent anti-inflammatory molecule — and PL-8177 is an attempt to turn that biology into a drug for inflammatory bowel disease.^[8] It is one of Palatin Technologies' investigational melanocortin agents: a synthetic cyclic heptapeptide that is a potent and selective MC1R agonist, activating the human receptor at low-nanomolar concentrations while leaving MC3R, MC4R and MC5R largely alone.^[2]

Why MC1R, and what "resolution" means

The receptor choice is deliberate. MC1R is the melanocortin receptor through which α-MSH does much of its anti-inflammatory work on immune cells, and a selective agonist can engage it without touching the appetite receptor MC4R or the adrenal MC2R. In the laboratory PL-8177 activates mouse and human MC1R at picomolar-to-nanomolar concentrations, and on macrophages it does two distinct things: it reduces the release of the inflammatory cytokines IL-1β, IL-6, TNF-α and CCL2, and it increasesefferocytosis, the clearing of dead cells that lets inflamed tissue return to normal rather than merely go quiet.^[2] That second action is what distinguishes a pro-resolving drug from an anti-inflammatory one, and it is the central idea of the inflammation page. In a mouse model of inflammatory arthritis, PL-8177 reduced clinical score, paw swelling and the recruitment of immune cells into the joint^[2] — evidence that the mechanism works in vivo, well before the gut was chosen as the first indication.

An oral peptide that doesn't need to be absorbed

The clever part is the delivery. Peptides are usually poor oral drugs because the gut digests them before they can reach the bloodstream — but PL-8177 turns that problem into a non-issue by not trying to reach the bloodstream at all. It is enclosed in a polymer formulation that carries it through the stomach and small intestine and releases it in the colon. In rats and dogs, orally dosed PL-8177 was found at higher concentrations in the colon than in the upper gut; in a phase 0 study in healthy men given a 70-microgram dose of radiolabelled drug, PL-8177 and its main metabolite were detected in the faeces and not at all in plasma or urine, which means the peptide was released from its coat and acted and was broken down entirely within the gut.^[1] Because its target — MC1R on the colon's immune and epithelial cells — is right there, staying in the gut is a feature, not a failure. It is the exception that clarifies the rule explained on the oral peptides page: oral peptides struggle when they need to travel, not when they act where they land.

What it did in the animal colon

In two rat models of colitis, oral PL-8177 at a 50-microgram dose lowered macroscopic colon damage scores and improved colon weight, stool consistency and occult bleeding compared with vehicle. Under the microscope the treated colons kept their structure and barrier, with less immune-cell infiltration and more intact enterocytes. The most telling result came from single-nucleus RNA sequencing of the tissue: treatment moved the colon's cell populations and gene-expression profile back toward those of healthy controls, with immune-marker genes and immune pathways under-represented relative to untreated disease.^[1] That is the molecular signature of resolution rather than suppression, and it set up the human trial.

The ulcerative colitis signal

PL-8177's lead programme is in ulcerative colitis, an inflammatory disease of the colon. A randomised, double-blind, placebo-controlled Phase 2 study gave once-daily oral PL-8177 for eight weeks to patients with active disease. The topline, reported in 2025, was clinical remission in 33% of treated patients (three of nine) against none on placebo, clinical response in 78% against 33%, and symptomatic remission in 56% against 33%; among patients with moderate disease, most showed improvement across all three segments of the colon examined. No adverse events were attributed to the drug.^[3] The honest caveat matters, though: Palatin stopped enrolment at 12 patients — nine on drug, three on placebo — rather than the 28 planned, as it redirected resources toward its melanocortin obesity programmes and out-licensing discussions.^[4] With those numbers the study was not powered to demonstrate statistical significance, so the result is an encouraging signal rather than proof. The developer's own framing is that the programme is now available for partnering, which is where it stands in 2026.^[7]

Beyond the gut

The same gut-restricted idea does not carry to other tissues, but the molecule does. PL-8177 holds an FDA orphan-drug designation for non-infectious uveitis,^[6]and in a mouse model of autoimmune uveitis it suppressed the disease and induced the regulatory immune response that follows — though, unlike α-MSH or a pan-agonist, its effect was temporary, which the authors read as evidence that ocular inflammation needs MC5R as well as MC1R.^[5] It is the finding that explains why Palatin's eye drop, PL-9643, is a pan-agonist while its gut drug is MC1R-selective: the receptor profile is chosen per tissue.

The honest bottom line

PL-8177 is early, and its own developer has shifted focus, so its future depends on a partner. But it is a clean illustration of the melanocortin system's pro-resolving arm being engineered into a drug — with the mechanism shown on cells, in arthritic joints and in inflamed colons before a small, promising human trial — and of a smart way around the oral-peptide problem when the target sits in the gut. For the biology it draws on, see α-MSH and the anti-inflammatory arm; for where it sits among everything in development, see the melanocortin pipeline.